- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Understanding Myelofibrosis: Disease Spectrum and Impact on Quality of Life
Aaron Gerds, MD, MS, compares myelofibrosis with other myeloproliferative neoplasms, explores its prevalence in the US, and reviews the diverse clinical presentations and the impact on patients’ quality of life.
EP: 1.Myelofibrosis: Characteristics and Subtypes
EP: 2.NCCN Guidelines Update Adds Momelotinib Below Ruxolitinib for High-, Low-Risk Myelofibrosis
EP: 3.Understanding Myelofibrosis: Disease Spectrum and Impact on Quality of Life
EP: 4.Prognosis and Treatment Strategies in Myelofibrosis: Risk Assessment and Therapeutic Goals
EP: 5.NCCN Guidelines 2023: Updates in Myelofibrosis Management
EP: 6.NCCN Guidelines: Categories and Recommendations in Myelofibrosis
EP: 7.Integrating Momelotinib: NCCN Guidelines and Drug Comparison
EP: 8.Monitoring Myelofibrosis Treatment Response: Guidelines and Considerations
EP: 9.Future of Myelofibrosis: Anticipated Data and Emerging Therapies
This is a video synopsis/summary of a Guidelines featuring Aaron Gerds, MD, MS.
Gerds sheds light on myelofibrosis (MF), a clonal myeloid disorder categorized under myeloproliferative neoplasms. He draws comparisons between MF, polycythemia vera (PV), and essential thrombocythemia (ET), emphasizing the shared pathobiologic factor of constitutive activation of the JAK-STAT pathway. MF clinically manifests with diverse symptoms, including elevated blood counts, constitutional symptoms like night sweats and weight loss, and splenomegaly, affecting the patient's quality of life significantly.
Gerds discusses the prevalence of MF, estimating approximately 300,000 people in the United States living with myeloproliferative neoplasms. He notes that while MF may have a higher incidence, the shortened life expectancy compared with PV and ET results in lower prevalence. The clinical presentation of MF varies, often diagnosed through routine blood work, symptom manifestation, or as a progression from ET or PV.
Exploring the burdens of MF, Gerds addresses cytokine-mediated symptoms, anemia challenges, and the overarching impact of having a chronic illness. Anemia, affecting around 40% of patients at diagnosis, presents a significant burden on patients' lives, particularly when transfusion-dependent. Furthermore, the chronic nature of MF, unless treated with stem cell transplant, adds an emotional burden often underrepresented in disease analyses. The conversation provides a comprehensive understanding of MF and its multifaceted effects on patients.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
Taletrectinib Recommended in NCCN Guidelines for ROS1-Positive NSCLC
July 31st 2025Taletrectinib was added to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology as a preferred option for the first-line and subsequent treatment of advanced ROS1-positive non–small cell lung cancer (NSCLC).
Read More
Linvoseltamab Added as Preferred Agent in Newest MM Practice Guidelines
July 31st 2025On July 2, linvoseltamab-gcpt (Lynozyfic; Regeneron) received an accelerated approval from the FDA in relapsed/refractory multiple myeloma (MM), and the most recent update to the National Comprehensive Cancer Network guidelines for MM has added the BCMA-targeted bispecific antibody as a preferred treatment option.
Read More
NCCN Guidelines Prioritize Quad Therapy in Multiple Myeloma
November 26th 2024In the most recent update to the National Comprehensive Cancer Network (NCCN) guidelines for treating patients who have multiple myeloma, a quadruplet regimen became the preferred first-line treatment option for transplant-eligible and -ineligible patients.
Read More
